Werewolf Therapeutics, Inc. · NASDAQ:HOWL
ANSBERT GADICKE reported a 6.90% stake in Werewolf Therapeutics, Inc. (Schedule 13D/A)
Event Jan 14, 2026 · Filed Jan 16, 2026
ANSBERT GADICKE reported a 6.90% stake in Werewolf Therapeutics, Inc., 3,368,670 shares, with active intent on Jan 14, 2026. Filed Jan 16, 2026 (Schedule 13D/A).
- Stake
- 6.90%
- Shares
- 3,368,670
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 14 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| MPM BioVentures 2014, L.P. | 3.00% | 1,461,054 |
| MPM BioVentures 2014 (B), L.P. | 0.20% | 97,450 |
| MPM Asset Management Investors BV2014 LLC | 0.10% | 50,289 |
| UBS Oncology Impact Fund L.P. | 2.50% | 1,208,810 |
| MPM BioVentures 2014 GP LLC | 3.20% | 1,558,504 |
| MPM BioVentures 2014 LLC | 3.30% | 1,608,793 |
| Oncology Impact Fund (Cayman) Management L.P. | 2.50% | 1,208,810 |
| MPM BioImpact LLC | 2.50% | 1,208,810 |
| ANSBERT GADICKE | 6.90% | 3,368,670 |
| LUKE EVNIN | 4.40% | 2,159,860 |
| Todd Foley | 3.30% | 1,608,793 |
| MPM ASSET MANAGEMENT LLC | 0.50% | 231,408 |
| MPM ONCOLOGY INNOVATIONS FUND LP | 0.70% | 319,659 |
| MPM Oncology Innovations Fund GP LLC | 0.70% | 319,659 |
Source
Related
- Werewolf Therapeutics, Inc.
- Ansbert Gadicke
- Werewolf Therapeutics, Inc. shareholders
- Schedule 13D/A · Ansbert Gadicke · May 12, 2026
- Schedule 13D/A · Ansbert Gadicke · May 5, 2026
- Schedule 13D/A · Ansbert Gadicke · Dec 29, 2025
- Schedule 13D/A · Ansbert Gadicke · Dec 3, 2025
- Schedule 13D/A · Ansbert Gadicke · Nov 17, 2025
- Schedule 13G · Moll Peter · Sep 21, 2026
- Form 4 · Luke Evnin · Jul 8, 2026
- Schedule 13D/A · Ra Capital Management, L.P. · Jul 2, 2026
- Form 4 · Luke Evnin · Jun 29, 2026
- Schedule 13D/A · Ra Capital Management, L.P. · Jun 26, 2026